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Abstract
Background: Several human pathologies, including neoplasia and ischemic cardiovascular diseases,
course with an unbalance between oxygen supply and demand (hypoxia). Cells within hypoxic
regions respond with the induction of a specific genetic program, under the control of the Hypoxia
Inducible Factor (HIF), that mediates their adaptation to the lack of oxygen. The activity of HIF is
mainly regulated by the EGL-nine homolog (EGLN) enzymes that hydroxylate the alpha subunit of
this transcription factor in an oxygen-dependent reaction. Hydroxylated HIF is then recognized and
ubiquitinilated by the product of the tumor suppressor gene, pVHL, leading to its proteosomal
degradation. Under hypoxia, the hydroxylation of HIF by the EGLNs is compromised due to the
lack of oxygen, which is a reaction cosubstrate. Thus, HIF escapes degradation and drives the
transcription of its target genes. Since the progression of the aforementioned pathologies might be
influenced by activation of HIF-target genes, development of small molecules with the ability to
interfere with the HIF-regulatory machinery is of great interest.
Results: Herein we describe a yeast three-hybrid system that reconstitutes mammalian HIF
regulation by the EGLNs and VHL. In this system, yeast growth, under specific nutrient restrictions,
is driven by the interaction between the β domain of VHL and a hydroxyproline-containing HIFα
peptide. In turn, this interaction is strictly dependent on EGLN activity that hydroxylates the HIFα
peptide. Importantly, this system accurately preserves the specificity of the hydroxylation reaction
toward specific substrates. We propose that this system, in combination with a matched control,
can be used as a simple and inexpensive assay to identify molecules that specifically modulate EGLN
activity. As a proof of principle we show that two known EGLN inhibitors, dimethyloxaloylglycine
(DMOG) and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-carboxymethylamide (S956711), have
a profound and specific effect on the yeast HIF/EGLN/VHL system.
Conclusion: The system described in this work accurately reconstitutes HIF regulation while
preserving EGLN substrate specificity. Thus, it is a valuable tool to study HIF regulation, and
particularly EGLN biochemistry, in a cellular context. In addition, we demonstrate that this system
can be used to identify specific inhibitors of the EGLN enzymes.
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Most mammalian tissues are strictly dependent on oxida-
tive metabolism and require constant oxygen supply to
maintain cell function. Thus, acute oxygen deprivation,
even for brief periods of time, can be deleterious. In con-
trast, cells can adapt to moderate chronic hypoxia through
the induction of a specific gene expression program. The
induction of this set of genes adjusts the metabolism by
increasing anaerobic glycolysis [1] and fine-tuning mito-
chondrial respiration [2,3]. In addition, hypoxic cells
induce vascularization of the poorly oxygenated tissue
through the expression of proangiogenic molecules such
as VEGF [4]. The family of Hypoxia Inducible Factors
(HIFs) is responsible for the induction of the vast majority
of the genes involved in these adaptive responses [5,6].
HIF transcription factors are heterodimers of an oxygen
dependent alpha subunit (HIFα) and a beta (HIFβ) chain
that is shared with other transcription factors of the basic-
helix-loop-helix family. There are three different HIFα iso-
forms (HIF1α, HIF 2α and HIF 3α), encoded by inde-
pendent genes, whose regulation by oxygen is thought to
be similar. Oxygen affects the half life [7,8] as well as the
transcriptional activity [9] of HIFα proteins. In both cases,
the effect is mediated by hydroxylation of specific resi-
dues, within HIFα, by a family of 2-oxogluatarate-depend-
ent dioxygenases that require molecular oxygen as
cosubstrate. These modifications affect the ability of HIF
to interact with other proteins. Specifically, hydroxylation
of a conserved asparagine residue (N803 in human HIF1α
protein) within the C-terminal transactivation domain by
the Factor Inhibiting HIF (FIH) [10,11] prevents its inter-
action with the p300 coactivator [9]. On the other hand,
the activity of the EGL-nine homologues (EGLNs, [12])
results in the hydroxylation of two conserved proline res-
idues (P402 and P564 in human HIF1α) within the Oxy-
gen-Dependent Degradation domain (ODD) of HIFα
proteins[13]. Proline hydroxylation allows the binding of
the E3 ubiquitin ligase pVHL to HIFα leading to its ubiq-
uitination and proteosomal degradation [8,14,15]. Since
FIH and EGLNs require oxygen as cosubstrate, under
hypoxia their activity is reduced [16,17]. As a consequence
the interaction with pVHL is lost, leading to HIF stabiliza-
tion, while the interaction with p300 is allowed resulting
in enhanced transcriptional activity. Although the regula-
tion of HIF transcriptional activity seems to be critical for
the induction of some HIF-target genes during hypoxia
[18], the major effect of oxygen is the regulation of HIFα
stability through the activity of the EGLNs. To date three
independent enzymes termed EGLN1, 2 and 3 (also
known as PHD2, 1 and 3 respectively) have been
described to mediate HIFα proline hydroxylation
[7,19,20]. Intriguingly, these enzymes display substrate
specificity: while EGLN1 and 2 are capable of hydroxylat-
ing both HIFα prolines, EGLN3 is unable to act upon the
N-terminal residue (P402 in human HIF1α) [17,21-23].
In this regard, recent publications describe novel potential
targets for these enzymes that seem to be regulated by spe-
cific isoforms [24,25].
In addition to the relevance of this pathway in the physi-
ological response to reduced oxygen supply, it probably
plays a major role during the progression of several
pathologies that course with hypoxia. Specifically, activa-
tion of HIF has been implicated in the induction of the
glycolitic and angiogenic phenotype of cancer [4,26], gen-
eration and progression of tumors [27] and resistance to
the isquemic insults (preconditioning) [28,29] among
other phenomena. Thus, the identification of small mole-
cules that modulate this pathway is of great therapeutical
interest. In fact, several molecules with the ability to mod-
ulate HIF activity have been already described. In animal
models, HIF inhibitors have been proven useful in the
treatment of tumors [30], while molecules with the ability
to induce HIF result in angiogenesis in vivo [31].
In this work, we describe the generation of a three-hybrid
system that accurately reconstitutes mammalian HIFα reg-
ulation by EGLN hydroxylation and subsequent VHL
binding. This system can be of aid in the study of EGLN
biochemistry and the characterization of novel substrates.
In addition, we demonstrate that it can be used as an effi-
cient assay to screen for small molecules with the ability
to regulate HIF.
Results
Generation of a yeast three hybrid-based system that 
reconstitutes HIF regulation
Several EGLN assays have been described which include
the determination of enzyme activity by measure of
cosubstrates (dioxygen and 2-oxoglutarate) consump-
tion/CO2 production and the detection of HIF hydroxyla-
tion using mass spectrometry or capture of VHL [32,33].
In addition, strategies to determine EGLN activity within
cells have also been developed. These include the detec-
tion of reporter proteins fused to ODD [34] and the use of
antibodies raised against hydroxyproline-containing
ODDs [35]. The major limitation of the in vitro assays is
that they are performed in a non physiological environ-
ment. On the other hand, the cell-based assays have to
deal with the endogenous HIF machinery. To circumvent
these problems we sought to reconstitute the HIF regula-
tory machinery in yeast cells, where expressed proteins are
in a cellular environment but where no endogenous pro-
teins related to the HIF pathway are expressed, therefore
eliminating possible sources of interference. To this end,
we cloned a fragment of human HIF1α (residues 554–
576) containing P564 in frame with yeast Gal4 activation
domain (AD-P564) (figure 1A). This fragment is sufficient
for EGLN recognition [23] and VHL binding [36]. In addi-
tion, we cloned a VHL fragment encoding for its β-domainPage 2 of 12
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binding domain (DB-VHL) (figure 1A). The VHL β-
domain is involved in HIF1α binding, while the α-
domain, missing in this construct, interacts with the elon-
gins B/C that are required to promote HIFα ubiquitina-
tion. Then we tested the interaction between these fusion
proteins as their ability to support the growth of a yeast
strain conditionally auxotrophic for histidine and ade-
nine (figure 1B). As shown in figure 1C, yeast cells trans-
formed with AD-P564 in combination with DB-VHL
failed to grow in plates lacking histidine, suggesting lack
of significant interaction between the two fusion proteins.
This result was expected since no EGLN orthologs are
present in yeast and VHL binding to HIF1α is strictly
dependent on proline hydroxylation [8,14]. In addition,
these data indicates that residual binding of VHL to non-
hydroxylated AD-P564 is below detection limit in our
assay conditions. Importantly, the expression of EGLN3
(construct E3/DB-VHL, figure 1A), together with the two
fusion proteins, is sufficient to promote direct binding of
DB-VHL to AD-P564, as indicated by the growth of trans-
formed yeast in restrictive plates (figure 1C). The effect
was not restricted to EGLN3 since the expression of
EGLN1 also triggered the interaction between the fusion
Characterization of a yeast three-hybrid system that reconstitutes HIF regulatory machineryFigure 1
Characterization of a yeast three-hybrid system that reconstitutes HIF regulatory machinery. A, Schematic dia-
gram representing the yeast three-hybrid constructs. Numbers in brackets correspond to residue positions for the encoded 
proteins. TRP1 and LEU2, genes encoding for the enzymes that allow cell growth in the absence of Trp and Leu respectively. B, 
Schematic diagram of the interaction between the different system components. 2OG, 2-oxoglutarate. C and D, Serial dilutions 
of clones transformed with the indicated constructs were grown on plates lacking Leu and Trp (CONTROL), plates lacking 
Leu, Trp and His (INTERACTION, medium str.) or plates lacking Leu, Trp, His and adenine (INTERACTION, high str.). The 
results shown are representative of at least three independent experiments.Page 3 of 12
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P564 interaction was mediated by the hydroxylation of
AD-P564 by EGLNs, we repeated the experiment using a
mutant HIF peptide in which P564 was replaced by an
alanine residue (AD-mutP564A, figure 1A). As shown in
figure 1D, DB-VHL was unable to interact with AD-
mutP564A regardless of the presence of either EGLN.
Moreover, in spite of relaxed target requirements [23,37],
it has been described that EGLN isoforms display a spe-
cific preference for the two target sequences in HIF1α
[17,21-23]. Therefore, we next wanted to determine
whether in this system the EGLNs retained their native
substrate specificity. Figure 1D shows that EGLN3 effi-
ciently hydroxylates the peptide containing the sequence
surrounding proline 564 (AD-P564), but it has no detect-
able activity toward a peptide comprising residues 392–
414 derived from HIF1α (AD-P402). In contrast, EGLN1
was able to hydroxylate both sequences allowing their
binding to VHL (figure 1D). Interestingly, the activity of
EGLN1 toward AD-P402 was slightly lower than its activ-
ity using AD-P564 substrate as evidenced by the different
growth of yeast transformed with each sequence in the
high stringency plates (figure 1D). These results are in per-
fect agreement with previous reports describing the activ-
ity of the EGLN isoforms against different substrates
[23,37-39]. Finally, further confirmation that EGLNs
retained their substrate specificity was obtained through
the analysis of the effect of L574A and L562R mutations
(Additional file 1).
All together, these results indicate that this system faith-
fully reconstitutes the regulation of HIFα proteins by the
sequential action of EGLN enzymes and VHL binding. In
addition, data show that the β-domain of VHL is sufficient
for target recognition and binding.
The reconstituted HIF/EGLN/VHL system can be exploited 
to identify specific EGLN inhibitors
The system described above relies on EGLN activity for
DB-VHL/AD-P564 interaction, thus we reasoned that
EGLN inhibitors should interfere with yeast growth. How-
ever, in cell-based assays, the inhibitory effects of drugs
have to be carefully controlled for unspecific side effects
on cell physiology or on the assay system itself. In order to
have a control for the drug specificity and rule out poten-
tial side effects on yeast growth, we generated a set of con-
structs analogous to those described above but based on a
protein machinery unrelated to the HIF pathway. In this
control system, yeast growth is dependent on the interac-
tion between an immunoreceptor tyrosine-based activa-
tion motif (ITAM), derived from the type Iγ IgE receptor
(FcεRIγ), and the Src-Homology domain 2 (SH2) from
the Syk protein. Importantly, the binding of Syk-SH2 tan-
dem domains to the FcεRIγ-ITAM is dependent on the
tyrosine phosphorylation of the latter [40]. The vectors
generated for this system (figure 2A) encode for a Syk-
derived tandem SH2 domains fused to the activation
domain of Gal4 (AD-SH2) and for an ITAM from FcεRIγ
fused to the Gal4 DNA binding domain (DB-ITAM).
Finally, the cytoplasmic tyrosine kinase Lck was cloned
into the pBridge vector to induce DB-ITAM phosphoryla-
tion and trigger its binding to AD-SH2 (figure 2B). Since
yeast do not contain orthologues of the proteins of this
system, AD-SH2 did not significantly interact with DB-
ITAM unless the tyrosine kinase Lck was co-expressed in
the assay (figure 2C), as previously reported [40]. Thus,
the Lck and EGLN-based assays are analogous in that both
have three components: an enzyme and two fusion pro-
teins whose interaction allows yeast growth in restrictive
media. Additionally, in both systems the interaction
between the fusion proteins, and thus yeast growth,
requires a modification of one of these proteins by the
enzyme (compare figures 1B and 2B).
Next we tested the ability of these combined systems to
detect molecules that interfere with HIF regulation. For
this purpose we selected two previously characterized
EGLN inhibitors, dimethyloxaloylglycine (DMOG) [41]
and 6-chlor-3-hydroxychinolin-2-carbonic acid-N-car-
boxymethyl-amide (S956711) [31]. In order to facilitate
the quantification of the effects of inhibitors on these sys-
tems, we set up the experiments in liquid media so that
yeast growth could readily be determined by the optical
density of the cell culture. Since the growth rate of yeast
transformed with different constructs in each culture
media varies, we adjusted the initial concentration of each
yeast strain for each media so that all cultures achieved
logarithmic growth in overlapping time windows (Addi-
tional file 2). As shown in figure 3A, treatment with
increasing doses of S956711 had a strong effect on the
growth of yeast expressing AD-HIF and DB-VHL/EGLN3
in restrictive media. In contrast, when these cells were cul-
tured in control media, where no interaction between
fusion proteins was required for growth, S956711 had
only a minor effect when used at 100 µM (figure 3A).
Thus, the effect of S956711 is not due to an unspecific
effect on yeast viability/growth. To further confirm the
specificity of the effect upon the HIF system, we tested the
effect of S956711 on yeast transformed with AD-SH2 and
DB-ITAM/Lck. As shown in figure 3, S956711 had no sig-
nificant effect in this control system regardless of the cul-
ture media. These results rule out that the inhibition of the
EGLN system could be due to side effects of S956711 on
transcription/translation of the three-hybrid elements.
The specific inhibitory effect of S956711 was highly repro-
ducible and unspecific effects were undetectable at doses
below 100 µM (figure 3B). Similarly to the results
observed for S956711, treatment with DMOG also
resulted in a dose-dependent inhibition of the interaction
between AD-HIF and DB-VHL (figure 4A). As shown forPage 4 of 12
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ulatory machinery, since no effect was observed on the
binding of AD-SH2 to DB-ITAM (figures 4A and 4B).
DMOG is a 2-oxoglutarate analogue that probably inhib-
its EGLN activity by competition with the reaction cosub-
strate 2-oxoglutarate [42]. Thus, DMOG should affect
EGLN catalitic activity (substrate hydroxylation), but not
substrate binding. With the purpose of testing this
hypothesis, we investigated the effect of DMOG on
EGLN3 binding to HIF using a two hybrid-based assay
[23]. In this assay, yeast growth in restrictive media is
dependent on the direct interaction between a Gal-4 DNA
binding domain-EGLN3 (DB-E3) and AD-HIF fusion pro-
teins (figures 5A and 5B). The interaction between DB-E3
and AD-HIF is specific since a single mutation on the tar-
get proline in HIF sequence abolishes yeast growth (figure
5C) [23]. Importantly, this assay allows the direct compar-
ison of DMOG effect on EGLN3 ability to bind HIF and
act upon it. As shown in figure 5D, DMOG treatment had
no effect on the direct binding of EGLN3 to its substrate,
as demonstrated by the lack of effect on the growth of
yeast expressing DB-EGLN3 and AD-HIF (E3/HIF system).
However, at the same doses it clearly affected the hydrox-
ylation of AD-HIF by EGLN3 (figure 5D, VHL/HIF sys-
tem). This result indicates that, as expected, DMOG does
Characterization of a control yeast three-hybrid system based on an ITAM/SH2 interaction that depends on Lck activityFigure 2
Characterization of a control yeast three-hybrid system based on an ITAM/SH2 interaction that depends on 
Lck activity. A, Schematic diagram representing the constructs. Abbreviations are as in figure 1. B, Schematic diagram of the 
interaction between the different system components. C, Serial dilutions of clones transformed with the indicated constructs 
were grown on different astringency plates. Symbols, abbreviations and panel labels are as in figure 1. The results shown are 
representative of at least three independent experiments.Page 5 of 12
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of this drug on the reconstituted HIF system (figure 4) is
likely due to its effect on EGLN activity rather than the
EGLN3/HIF interaction. It should be noted however that
these results do not exclude a potential effect of DMOG
on VHL/hydroxylated-HIF interaction.
In addition to S956711 and DMOG, we also tested more
general inhibitors, such as deferoxamine and cobalt chlo-
ride, that have been widely used to activate HIF [8,14].
EGLNs contain a tightly bound Fe+2 atom in the catalitic
site that is required as a cofactor in the hydroxylation reac-
tion. Consequently, iron sequestration by the chelating
agent deferoxamine results in EGLN inhibition [8,14]. On
the other hand, the mechanism of EGLN inhibition by
cobalt chloride is controversial [43,44]. It might act by
substitution of the iron from the enzyme catalytic site
and/or interfere with ascorbate transport [44], which is
required to prevent the oxidation of the catalytic site of
the enzyme. In our assays, cobalt chloride had an impor-
tant toxic effect on yeast and showed little specific inhibi-
tion of the EGLN system (data not shown), thus we did
not study it in further detail. On the other hand, we were
unable to detect any significant effect of deferoxamine on
yeast growth at concentrations up to 1 mM (data not
shown). A possible explanation for the lack of effect of
deferoxamine is that treatment might induce an adaptive
response in yeast that increases their iron uptake [45]. In
spite of their wide use as hypoxia mimetics, a recent report
describes that cobalt and deferoxamine are ineffective
inhibitors of EGLNs in vitro [43], which is in agreement
with the lack of significant effect of these drugs in our sys-
tem.
All together these results indicate that the combination of
the control (Lck-dependent) and experimental (EGLN-
dependent) systems constitutes an efficient assay to iden-
tify small molecules that have a specific effect on EGLN
activity, while revealing those that have unspecific or toxic
effects. Importantly, the effect of S956711 and DMOG in
our system was achieved at doses equivalent to those
required for the inhibition of EGLNs in mammalian cells
[31,41].
Discussion
Herein we describe a yeast three-hybrid system that recon-
stitutes HIF regulation through proline hydroxylation and
VHL interaction. This system accurately preserves EGLN
substrate specificity, supporting its biochemical relevance.
The system described in this work relies on the interaction
between a 22 residue fragment derived from HIF1α and
the β-domain of VHL. The HIF1α fragment can be
replaced by the full length protein without affecting the
performance of system, except for a slight reduction in the
interaction strength (data not shown). However, we were
unable to express full length VHL in yeast (data not
shown), probably due to misfolding of its α-domain in
the absence of elongins B and C [46,47]. To circumvent
this problem and since only the α domain of VHL inter-
acts with elongin B [46], we generated a truncated VHL
lacking this domain. This VHL form contains an intact β-
domain [36] that, according to our data, is sufficient to
Effect of S956711 on the EGLN-dependent and Lck-depend-ent three-hybrid systemsFigure 3
Effect of S956711 on the EGLN-dependent and Lck-
dependent three-hybrid systems. Yeast clones trans-
formed with constructs encoding for AD-P564 and E3/DB-
VHL (E3) or AD-SH2 and Lck/DB-ITAM (Lck) were used to 
inoculate control media lacking Leu and Trp (control) or 
restrictive media (restrictive) lacking Leu, Trp, and His (in 
the case of E3 clones, restrictive media also lacked adenine). 
Duplicate cell cultures were grown in the presence of 0, 25, 
50 or 100 µM S956711. The density of cultures was deter-
mined 16–24 hours after inoculation. A, The cell density 
(absorbance at 620 nm) of each culture condition is repre-
sented as the percentage of density obtained for the cells 
grown in the absence of drug. The graph represents the aver-
age values of nine independent experiments. Error bars rep-
resent the S.E.M. B, the individual data values of density for 
the 50 µM S956711 cultures in A are represented. Horizon-
tal bars represent the mean. Statistically significant different 
mean values (p < 0.001) are indicated with asterisks.Page 6 of 12
(page number not for citation purposes)
BMC Cell Biology 2008, 9:18 http://www.biomedcentral.com/1471-2121/9/18bind HIF. Although the interaction of this truncated VHL
construct with HIF is robust, we can not rule out that its
affinity for HIF is different to that of the native VBC com-
plex. In summary, this system is probably composed of
the minimal functional units required to reconstitute
HIF1α regulation.
Given the relevance of hypoxia in several pathologies, the
identification of small molecules with the ability to mod-
ulate HIF activity has drawn much interest. In this regard,
we have demonstrated that the three-hybrid assay
described herein can be used to effectively identify small
molecules that interfere with HIF regulation. Importantly,
in contrast to current enzymatic assays, this system can be
easily adapted to be performed on 96-well plates so it can
be used for high-throughput screening of small mole-
cules. In this regard, it should be noted that the direct
determination of yeast growth provides a narrow linear
range. Thus, in order to adapt this system to large high
throughput screenings it would be much more convenient
to determine β-galactosidase activity. Several yeast strains
contain a LacZ gene under the control of the Gal4 pro-
moter, thus β-galactosidase activity reflects the strength of
the interaction between fusion proteins. In addition, the
controls included in this work have proved useful in dis-
criminating between genuine specific inhibitors of the
EGLN-dependent system and molecules with a broad
spectrum of targets such as cobalt chloride. Since the con-
trol (Lck-dependent assay) is based in exactly the same
methodology than the test (EGLN-dependent assay), the
combination of both systems constitutes a convenient
assay for large screenings. Finally, comparison of the
effects of the drug on the whole reconstituted system
(three-hybrid) and on the direct interaction between
EGLNs and HIFα (two-hybrid) could be helpful in the
elucidation of the inhibition mechanism of candidate
drugs (figure 5).
When considering the modulation of the HIF pathway, it
is important to take into account that the relative contri-
bution of each EGLN to HIF regulation seems to be differ-
ent [17,22,23] and probably cell-type specific [21].
Moreover, it is likely that different EGLN isoforms might
have a specific set of target molecules [24,25]. Thus, the
development of isoform-specific inhibitors is of great
interest. However, since the catalitic site of the three
EGLNs members is very similar, the identification of spe-
cific inhibitors based on analogues of the 2-OG is proba-
bly difficult [48]. On the other hand, our work [49] and
that of others [50] have recently demonstrated that the
different substrate specificity shown by each EGLN iso-
form relies on a defined substrate-binding surface rela-
tively far from the catalitic site. Thus, it is theoretically
possible to identify molecules that block the HIF-binding
region in specific EGLN isoforms. In this regard, use of our
system, in particular the direct interaction assay (figure 5
and reference[23]), could aid in the identification/charac-
terization of such a molecule.
During the writing of this manuscript a paper was pub-
lished describing a yeast two-hybrid system that, similarly
to ours, reconstitutes HIF recognition by VHL [51]. How-
ever, an important practical difference between the two
systems is that the one described by Bex and coworkers
Effect of DMOG on the EGLN-dependent and Lck-depend-ent three-hybrid systemsFigure 4
Effect of DMOG on the EGLN-dependent and Lck-
dependent three-hybrid systems. Yeast clones trans-
formed with constructs encoding for AD-P564 and E3/DB-
VHL (E3) or AD-SH2 and Lck/DB-ITAM (Lck) were used to 
inoculate control media lacking Leu and Trp (control) or 
restrictive media (restrictive) lacking Leu, Trp, and His (in 
the case of E3, clones restrictive media also lacked adenine). 
Duplicate cell cultures were grown in the presence of 0, 250, 
500 or 1000 µM DMOG. The density of cultures was deter-
mined 16–24 hours after inoculation. A, The cell density 
(absorbance at 620 nm) of each culture condition is repre-
sented as the percentage of density obtained for the cells 
grown in the absence of drug. The graph represents the aver-
age values of eight independent experiments. Error bars rep-
resent the S.E.M. B, the individual data values of density for 
the 500 µM DMOG cultures in A are represented. Horizon-
tal bars represent the mean. Statistically significant different 
mean values (p < 0.001) are indicated with asterisks.Page 7 of 12
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functional full length VHL.
Conclusion
In summary, the results presented indicate that this sys-
tem constitutes a simple yet powerful assay to study EGLN
biochemistry in a cellular context without the interference
of the endogenous HIF system. The system is particularly
well suited to screen for modulators of the HIF regulatory
machinery. Finally, since the specificity of the reaction cat-
alyzed by the EGLNs is accurately preserved, this system
can also be used to characterize novel EGLNs targets.
Methods
Cells and reagents
The S. cerevisiae AH109 strain, yeast growth media rea-
gents YPD (yeast extract/peptone/dextrose), SD (synthetic
defined) amino acids, X-gal (5-bromo-4-chloroindol-3-yl
β-D-galactopyranoside) and plasmids (pGAD and
pBridge) were from BD Biosciences, (Palo Alto, CA).
Effect of DMOG on the direct binding of EGLN to HIFFigure 5
Effect of DMOG on the direct binding of EGLN to HIF. Schematic diagram representing the constructs (A) and the 
interaction between the different system components (B). C, Serial dilutions of clones transformed with the indicated con-
structs were grown on different stringency plates. The results shown are representative of at least three independent experi-
ments. D, Yeast clones transformed with empty pGAD and pBridge plasmids (Empty) or with constructs encoding for AD-
P564 and E3/DB-VHL (VHL/HIF) or AD-P564 and DB-E3 (E3/HIF) were used to inoculate control media lacking Leu and Trp 
(control) or restrictive media (restrictive) lacking Leu, Trp, and His (in the case of E3 clones restrictive media also lacked ade-
nine). Duplicate cell cultures were grown in the presence of 0 or 500 µM DMOG and the density of cultures was determined 
16–24 hours after inoculation. The density values obtained for cultures treated with DMOG were normalized as percentage of 
the density obtained for cultures in the absence of drug. The graph represents the individual data values of density for each of 
the four independent experiments. Horizontal bars represent the mean. Statistically significant different mean values are indi-
cated with one (p < 0.05) or two (p < 0.01) asterisks. Symbols, abbreviations and panel labels are as in figure 1.Page 8 of 12
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Constructs expressing HIF1α(554–576) and hSYK(11–
263) as Gal4AD fusion proteins were generated by PCR
amplification (figure 5 and reference [23]) of the indi-
cated coding region from human cDNA and cloned into
the EcoRI/BamHI or EcoRI sites of pGAD-T7 plasmid (BD
Biosciences) respectively. The Gal4DBD fusion proteins
were generated by PCR amplification (table 1) of the indi-
cated coding regions from the cloned full length sequence
(VHL) or from human cDNA (FceRIγ). VHL (encoding for
residues 63–157) and FceRIγ (encoding for residues 45–
86) amplicons were then cloned into the XmaI/SalI or
EcoRI sites respectively. Finally, the coding sequences for
EGLN3 and LCK were PCR-amplified (table 1) and cloned
into the BglII or NotI/BglII sites of pBRIDGE-VHL(63–
157) or pBRIDGE-FceRIγ (45–86) constructs respectively.
LCK was amplified from human cDNA and EGLN-3 was
amplified from its cloned cDNA, which was generously
provided by Steven L. McKnight. For the two hybrid
assays, the constructs expressing Gal4DBD fused to
EGLN-3 were generated by cloning its coding sequence
into the XmaI/SalI sites of the pBRIDGE plasmid (figure 5
and reference [23]).
In Table 2 are summed up all the constructs used in this
study.
Yeast transformation and plate interaction control assays
Freshly made competent yeast cells were transformed with
0.1 µg or 0.3 µg of GAL4AD or GAL4DBD constructs
respectively by a modified version of the lithium acetate
method (Gietz y col., 1992) and plated on minimal SD
media plates in the absence of Leu and Trp for selection of
transformants. Subsequently, an equal number of colo-
nies from each transformation was transferred to saline
solution (0.9% NaCl) and subjected to serial dilutions.
Aliquots of each cell suspension (typically 8 µl) were
plated on culture media with different stringencies: (1)
control plates lacking leucine/tryptophan (minimal strin-
gency; no interaction between fusion proteins required for
yeast growth); (2) restrictive plates lacking leucine, tryp-
tophan and histidine (medium stringency; interaction
required to support yeast growth); or (3) restrictive plates
lacking leucine, tryptophan, histidine and adenine (max-
imal stringency; strong interaction required to support
yeast growth).
Table 2: Plasmids used in this study.
Expression from PADH1 promoter Expression from PMET25 promoter
NAME VECTOR Protein Fragment MUTATIONS Protein Fragment
AD-P564 pGAD-T7 GAL4 AD- HIF 554–576 wt
AD-mutP564A pGAD-T7 GAL4 AD- HIF 554–576 P564A
AD-L574A pGAD-T7 GAL4 AD- HIF 554–576 L574A
AD-L562R pGAD-T7 GAL4 AD- HIF 554–576 L562R
AD-P402 pGAD-T7 GAL4 AD- HIF 392–414 wt
AD-SH2 pGAD-T7 GAL4 AD- SYK SH2 11–236 wt
DB-VHL pBRIDGE GAL4 DBD- VHL 63–157 wt
E3/DB-VHL pBRIDGE GAL4 DBD- VHL 63–157 wt EGLN3 Full length
E1/DB-VHL pBRIDGE GAL4 DBD- VHL 63–157 wt EGLN1 Full length
DB-ITAM pBRIDGE GAL4 DBD- ITAM 45–86 wt
LCK/DB-ITAM pBRIDGE GAL4 DBD- ITAM 45–86 wt LCK Full length
DB-E3 pBRIDGE GAL4 DBD- EGLN3 Full length wt
Table 1: Primers used for the generation of the constructs used in this study.
Gene Primer
Syk Fw 5'GAATTCAACCACCTGCCCTTCTTT 3'
Rv 5'GAATTCTGCCGATTTTTTGACATGG 3'
VHL Fw 5'AGCTGAATTCCTGCGCTCGGTGAACTCGCGC3'
Rv 5'AGCTCTCGAGGGATCCTCAAGTATACACTGGCAGTGTGATATTG3'
FcεRIγ Fw 5'GAATTCCGACTGAAGATCCAAGTGCGAAAG 3'
Rv 5'GAATTCCTACTGTGGTGGTTTCTCATGCTTCAG 3'
Lck Fw 5'TGATCAGCGGCCGCCATGGGCTGTGGCTGCAGCTCACAC 3'
Rv 5'GCGGCCGCTGATCATCAAGGCTGAGGCTGGTACTGGCC 3'
EGLN3 Fw 5'AGCTAAGCTTACCATGAGATCTTCTAGAATGCCCCTGGGACACATCATGAGG 3'
Rv 5'GACTGAATTCTGATCAGTCGACGTCTTCAGTGAGGGCAGATTCAG 3'Page 9 of 12
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An equal number of fresh (up to two weeks old) yeast col-
onies were transferred to 6 ml of minimal stringency liq-
uid media and grown overnight at 250 rpm and 30°C.
Yeast cells were subsequently pelleted, thoroughly washed
with maximal stringency medium and resuspended in 1
ml of the appropriate liquid culture media at a fixed con-
centration as determined in pilot experiments (Additional
file 2). Cultures were then grown at 250 rpm and 30°C for
the indicated times. Growth of cell cultures was measured
as the increase in 620 nm absorbance of 150 µl culture
aliquots taken at initial (t = 0) and the indicated times. For
the drug assays, drugs were added to the culture media at
t = 0.
Statistical analysis of data
Experimental data were analyzed with the Prism™ Graph-
Pad (version 4.01) software. Data were analyzed by the
analysis of variance test (ANOVA) followed by the Tukey's
multiple comparison test.
List of abbreviations
HIF, hypoxia inducible factor; EGLN, EGL-nine Homolog;
ODD, Oxygen-dependent Degradation Domain; AD,
Gal4 activation domain; DB, Gal4 DNA binding domain;
DMOG, dimethyloxaloylglycine.
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